Case Report
Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma
Table 1
Demographics, presentations, treatments, and outcomes of reported cases of metastatic EC.
| Serial number | Age/sex [reference] | Presentation of primary cutaneous lesion | Metastatic sites | Treatment | Outcome |
| 1 | 60/F [5] | Ulcerative, nodular, scaly, erythematous | Axillary and subclavicular LNs | Capecitabine | PFS (18 months) | 2 | 73/M [12] | Ulcerative, nodular, erythematous | Parotid gland, cervical LNs, lung | Capecitabine | CR | 3 | 64/F [13] | ND | Intraparotid LN | Tamoxifen | PFS (3 years) | 4 | 43/F [10] | ND | Occipital LNs, cervical nerve root, vertebrae | Sunitinib | PFS (8 months) | 5 | 45/F [11] | ND | Cervical LNs, bone, choroid | Doxorubicin | POD (deceased after 2 months) | 6 | 59/F [4] | Bluish nodule, 2 cm diameter | Mediastinal LNs, lung | Cyclophosphamide | POD (deceased after 1 month) |
|
|
CR: complete response; F: female; LN: lymph node; M: male; ND: not described; PFS: progression free survival; POD: progression of disease.
|